New Psychoactive Substances Constant State of Flux: NBOMe Brazilian Case
DOI:
https://doi.org/10.17063/bjfs11(1)y202162-69Keywords:
new psychoactive substances, Drug Market, Forensic Report, NBOMe, Designer DrugsAbstract
The new psychoactive substances (NPS) market is in a constant state of flux, with new substances being synthesized regularly and marketed in many ways and forms. These substances often emerge quickly, just as they disappear, evidencing a clear attempt to circumvent the control trafficking enforcement agencies and the international community. Among the wide variety of NPS, the NBOMe series attracted attention from medical and legal authorities due to the high number of cases of intoxication, followed or not by death in several countries around the world, including Brazil. So, this brief communication aimed to evaluate the number of NBOMe Brazilian Federal Police (BFP) over the past eight years, and highlight the NPS constant state of flux, evidencing by the Brazilian NBOMe case. This is a retrospective study based on information from forensic analysis reports from seizures of BFP. The NBOMe seizures generated 4 forensic analysis requests in 2012, 21 in 2013, 45 in 2014, 61 in 2015, 80 in 2016, 22 in 2017, 19 in 2018 and 2 in 2019, totaling 254 forensic analysis reports analyzed. This NPS emerged quickly in Brazil from the year 2012, and tented to disappear in recent years, from the perspective of the BPF forensic analysis reports, evidencing the NPS constant state of flux, represented here by the Brazilian NBOMe case.
References
United Nations Office On Drugs And Crime. World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6). [Internet]. E.20.XI.6. Vienna: UNITED NATIONS; 2020. 56 p. Available at: www.unodc.org/wdr2020
Varì MR, Pichini S, Giorgetti R, Busardò FP. New psychoactive substances-Synthetic stimulants. WIREs Forensic Sci. 2019;1(2):e1197. https://doi.org/10.1002/wfs2.1197 DOI: https://doi.org/10.1002/wfs2.1197
Rose SR, Poklis JL, Poklis A. A case of 251-NBOMe (25-1) intoxication: A new potent 5-HT2A agonist designer drug. Clin Toxicol. 2013;51(3):174-7.
https://doi.org/10.3109/15563650.2013.772191 DOI: https://doi.org/10.3109/15563650.2013.772191
Bersani FS, Corazza O, Albano G, Valeriani G, Santacroce R, Bolzan Mariotti Posocco F, et al. 25C-NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Vol. 2014, BioMed Research International. Hindawi Publishing Corporation; 2014. https://doi.org/10.1155/2014/734749 DOI: https://doi.org/10.1155/2014/734749
Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol. 2015 Feb 1;53(2):85-92.
https://doi.org/10.3109/15563650.2015.1004179 DOI: https://doi.org/10.3109/15563650.2015.1004179
Wayhs CAY, Reis M Dos, Mariotti KDC, Romão W, Vaz BG, Ortiz RS, et al. NBOMe: perfil de apreensões da Polícia Federal no Brasil. Rev Bras Crim. 2016;5(3):22-9.
https://doi.org/10.15260/rbc.v5i3.136 DOI: https://doi.org/10.15260/rbc.v5i3.136
Coelho Neto J, Andrade AFB, Lordeiro RA, Machado Y, Elie M, Ferrari Júnior E, et al. Preventing misidentification of 25I-NBOH as 2C-I on routine GC-MS analyses. Forensic Toxicol. 2017;35(2):415-20. https://doi.org/10.1007/s11419-017-0362-0 DOI: https://doi.org/10.1007/s11419-017-0362-0
Wayhs CAY, Reis M, Mariotti KC, Romão W, Vaz BG, Barreto F, et al. NBOMe Designer Drugs: GC-MS and LC-QTOF/MS Detection on Blotter Paper by Brazilian Federal Police (Rio Grande do Sul, Brazil). Brazilian J Forensic Sci Med Law Bioeth. 2018;7(3):193-204. https://doi.org/10.17063/bjfs7(3)y2018193 DOI: https://doi.org/10.17063/bjfs7(3)y2018193
Marchi NC, Scherer JN, Fara LS, Remy L, Ornel R, Reis M, et al. Clinical and Toxicological Profile of NBOMes: A Systematic Review. Psychosomatics. 2019;60(2):129-38. https://doi.org/10.1016/j.psym.2018.11.002 DOI: https://doi.org/10.1016/j.psym.2018.11.002
ANVISA. Portaria No 344, de 12 de Maio de 1998 [Internet]. 1998 [cited 2021 Apr 27]. Available at: http://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html
ANVISA. Resolução da Diretoria Colegiada – RDC No 06 de 18 de Fevereiro de 2014 [Internet]. 2014 [cited 2021 Apr 27]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2014/rdc0006_18_02_2014.pdf
Westeren KI, Cader H, de Fátima Sales M, Similä JO, Staduto J. Summary, conclusions, and policy implications. In: Competitiveness and Knowledge [Internet]. E.19.XI.8. Vienna: Routledge; 2018. p. 177-90. https://doi.org/10.4324/9781315625331-7 DOI: https://doi.org/10.4324/9781315625331-7
Polícia Federal. Drogas Sintéticas: Relatório. 2018;19.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Brazilian Journal of Forensic Sciences, Medical Law and Bioethics
This work is licensed under a Creative Commons Attribution 4.0 International License.
